Hypokalemia in Patients with COVID-19.

BACKGROUND: Patients with COVID-19 experience multiple clinical conditions that may cause electrolyte imbalances. Hypokalemia is a concerning electrolyte disorder closely associated with severe complications. This study aimed to estimate prevalence, risk factors and outcome of hypokalemia in a cohort of patients with confirmed COVID-19.
METHODS: A retrospective analysis was conducted on 290 non-ICU admitted patients with COVID-19 at the tertiary teaching hospital of Modena, Italy, from February 16 to April 14, 2020.
RESULTS: Hypokalemia was detected in 119 out of 290 patients (41%) during hospitalization. Mean serum potassium was 3.1 ± 0.1 meq/L. The majority of patients (90.7%) patients experienced only a mild decrease in serum potassium level (3-3.4 mEq/L). Hypokalemia was associated with hypocalcemia, which was detected in 50% of subjects. Urine potassium-to-creatinine ratio, measured in a small number of patients (n = 45; 36.1%), revealed an increase of urinary potassium excretion in most cases (95.5%). Risk factors for hypokalemia were female sex (odds ratio (OR) 2.44; 95% CI 1.36-4.37; P 0.003) and diuretic therapy (OR 1.94, 95% CI 1.08-3.48; P 0.027). Hypokalemia, adjusted for sex, age and SOFA score, was not associated with ICU transfer (OR 0.52; 95% CI 0.228-1.212; P = 0.131), in-hospital mortality (OR, 0.47; 95% CI 0.170-1.324; P = 0.154) and composite outcome of ICU transfer or in-hospital mortality (OR 0.48; 95% CI 0.222-1.047; P = 0.065) in our cohort of patients.
CONCLUSIONS: Hypokalemia was a frequent disorder in subjects with COVID-19. Female sex and diuretic therapy were identified as risk factors for low serum potassium levels. Hypokalemia was unrelated to ICU transfer and death in this cohort of patients.

Introduction

COVID-19 is an emerging pandemic spreading worldwide from December 2019. On through 27 October 2020, the death of more than one million people and the increase in the number of newly infected people are posing a threat to global health [1].

Epidemiological studies documented that the majority of COVID-19 cases has a mild self-limited presentation (81%) but the development of severe respiratory symptoms (14%) such as dyspnea, tachypnea and hypoxia require hospital admission [2]. The lung is the principal target of the novel coronavirus, and atypical pneumonia is the most common clinical presentation [3]. Multiple organs such as the heart, brain, liver and kidneys can be involved during this infection [4]. Systemic release of cytokines is thought to be the cause of organ dysfunction and, therefore, the major determinant of morbidity in these patients [5]. Cytokines provoke a severe pro-inflammatory state leading to hypoxemia and sepsis requiring intensification of supportive therapy. Generally, hospitalized patients belong to a vulnerable subset of the population because they are older adults and have several underlying medical conditions [6]. Patients with COVID-19 can experience a long hospital stay. They usually undergo multiple treatments varying from delivering of ventilatory support to the administration of experimental agents for SARS-CoV-2 infection. In this setting, fever, hyperventilation, sweating, medication-related side effects  and dietary changes may cause concerning electrolyte imbalances.

Maturing experience in the care of COVID-19 patients showed that hypokalemia is a frequent lab abnormality. There is particular concern about this disorder as it may increase the susceptibility to potential fatal arrhythmia in COVID-19 patients [7, 8]. Hypokalemia has been described in a few case-series during the SARS-Cov-1 outbreak in 2003, but there is a lack of data on the exact mechanisms underlying this disorder [9, 10]. Possible causes of hypokalemia in the context of SARS-CoV2 infection may result from hyper-activation of the renin–angiotensin–aldosterone system (RAAS), gastrointestinal losses, anorexia secondary to concurrent illness and tubular damage caused by ischemia or nephrotoxicagents. With regard to this latter hypothesis, tubular damage may be linked to the direct cytotoxic effect of SARS-CoV-2, since the virus has been associate to diffuse tubular damage [11].

Considering these unanswered clinical questions, we evaluated a cohort of hospitalized patients to assess the prevalence of hypokalemia and its impact on clinical outcomes.

Methods

Study design

A single-center, retrospective, observational study was conducted at the University Hospital of Modena. We retrospectively reviewed all the electronic records of 320 non-critically ill patients admitted to our hospital from February 16 to April 14, 2020, with a diagnosis of SARS-CoV-2 infection, according to WHO interim guidelines [12].

The study was approved by the regional ethical committee of Emilia Romagna (prot. n. 0013376/20).

Data collection

We collected data on age, sex, laboratory values during admission (hemoglobin concentration, lymphocyte count, platelet count, arterial blood gas analysis, markers of inflammation, serum and urine creatinine, urea and urine electrolyte), comorbidities, sign and symptoms at presentation, vital signs and administered treatment (diuretic, electrolyte supplement). Rates of ICU transfer and living status at the end of the observation period were used as primary outcome variables.

Outcomes measures

The primary objective of our study was to evaluate the prevalence of hypokalemia. Secondary outcomes included assessment of hypokalemia on the risk of ICU transfer and in-hospital mortality of non-ICU admitted patients.

Variables and definition

Hypokalemia was defined as a serum potassium level < 3.5 mEq/l. The normal level of serum potassium ranges from 3.5 to 5.3 mEq/L. The diagnosis of hypokalemia was performed on a single value of serum potassium < 3.5 meq/L at any time during hospitalization. We excluded all serum values of potassium measured on plasma and by blood gas analyzer.

Severity was classified as mild when the serum potassium level was 3–3.4 mmol/L, moderate when the serum potassium level was 2.5–3 mmol/L, and severe when the serum potassium level was less than 2.5 mmol/L.

Hypocalcemia and hypomagnesemia were defined by a serum level of less than 8.5 mg/dl and 1.6 mg/dl, respectively. Acute kidney injury (AKI) was defined according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [13].

Potassium urinary excretion was measured as urine potassium-to-creatinine ratio. A value of potassium urinary excretion > 1.5 indicated inappropriate renal potassium loss [14-16]. Potassium urinary excretion was not measured in patients with chronic and acute kidney disease.

Sodium urinary excretion was measured with the fractional excretion of sodium (FeNa); a value < 1% declared a reduced excretion of sodium, whereas it resulted augmented for value ≥ 1%.

Sequential Organ Failure Assessment (SOFA) score was calculated at hospital admission. The term non-critically ill denoted non-ICU admitted patients. Institutional criteria for ICU admission and/or invasive ventilation: were (a) hemodynamic instability or major electrocardiographic abnormalities; (b) sepsis with neurologic involvement or lactic acidosis; (c) bradypnea or apnea with respiratory arrest; (d) persistence of respiratory distress; (e) the need to protect airways due to neurological deterioration or massive secretions.

Statistical analysis

Baseline characteristics were analyzed using descriptive statistics and reported as proportions and mean (standard deviation [SD]) when appropriate. Categorical variables were analyzed using χ2 test or Fisher’s test as appropriate. Analyses of continuous variables were compared using an unpaired t test and Mann–Whitney test, as appropriate. Risk factors for hypokalemia were evaluated using logistic regression analysis.

Odds ratios(OR) adjusted for sex, age and SOFA score at ward admission evaluated the strength of association between hypokalemia and the risk of ICU transfer, in-hospital mortality and composite outcome of ICU transfer or in-hospital mortality. A P value of less than 0.05 was considered statistically significant. SPSS 23® was used for statistical analysis.

Results

Patients

Serum potassium level was measured in 290 (1671 samples) non-ICU admitted patients aged 64.8 ± 13.8 years with confirmed COVID-19. The inclusion criteria identified 171 patients with normokalemia, who were selected as a control group. Hypokalemia (K < 3.5 mEq/L) was detected in 119 patients (41%) (Fig. 1). In these subjects, serum potassium ranged from 2.4 mEq/l to 3.5 mEq/l with a mean average of 3.1 (± 0.18) mEq/l. The mean time elapsed between admission and hypokalemia was on average 3.6 (± 5.4) days. One-third of cases (33.6%) of hypokalemia were detected at admission and about half within 1 day after admission (Supplementary Fig. 1).

Fig. 1

Flow chart of patients’ selection

Demographics and clinical manifestations of patients are reported in Table 1. Most patients (90.7%) had mild hypokalemia (serum potassium ranging from 3 to 3.4 mEq/l). The duration of this electrolyte disturbance ranged from 1 to 13 days. Low serum potassium levels lasted on average 2.27 days per patient. Time spent on hypokalemia per number of patients (%) was: 1 day (52%), 2 days (11.7%), 3 days (18.4%), 4 days (10.9%), 5 days (3.3%) and > 6 days (3.4%).

Table 1

Demographic and clinical characteristics of hypokalemic (K < 3.5; mEq/L) and normokaliemic (K 3.5–5.3 mEq/L) COVID-19 non-ICU admitted patients

Characteristic	Hypokalemic	Normokaliemic	P value
	N = 119	N = 171
Age, years (± SD)	65.8 (12.9)	64.1 (14.4)	0.258
Gender, n (%)
Male	73 (61.3)	138 (80.7)	0.001
Comorbidities, n (%)*
Diabetes	26 (27.9)	24 (16.3)	0.113
Hypertension	54 (83)	74 (76.2)	0.81
Cardiovascular  Disease	33 (38)	32 (23)	0.085
Chronic Kidney Disease	21 (21.4)	29 (20.4)	0.875
Sign and symptoms, n (%)*
Dyspnea	61 (56)	64 (50)	0.022
Diarrhea	17 (15.7)	15 (11.7)	0.182
Cought	66 (61.1)	68 (53.1)	0.009
Fatigue	25 (23.1)	39 (30.5)	0.774
Myalgia	12 (11.1)	8 (6.3)	0.098
Headache	9 (8.3)	15 (11.7)	0.83
From symptoms to admission, days (± SD)	7.6 (6.1)	7 (3.9)	0.406
Clinical parameter, (± SD)
Systolic pressure, mmHg	125 (18.4)	122.1 (20)	0.245
Diastolic pressure, mmHg	73.3 (11.7)	72.8 (11.3)	0.911
Respiratory rate, n (%)	24.5 (8.3)	23 (6.3)	0.428
Baseline PaO2/FiO2	217.9 (101.5)	235.6 (108.8)	0.215
SOFA Score	2.7 (2.1)	2.2 (2.1)	0.014
Body Temperature °C	37.1 (1)	36.9 (1)	0.287
Acid–base status
pH (± SD)	7.457	7.450	0.277
CO2 (± SD)	40.2	40.4	0.908
HCO3 (± SD)	27.2	26.7	0.360
Normal. n (%)	44 (40.3)	68 (45.6)	0.713
Metabolic alkalosis. n (%)	49 (44.9)	55 (36.9)	0.135
Respiratory alkalosis. n (%)	12 (11)	8 (5.3)	0.098
Respiratory acidosis. n (%)	4 (3.6)	9 (6)	0.569
Treatment, n (%)*
Oral KCl supplement	28 (23,5)	7 (4)	0.0001
IV KCl supplement	14 (11.7)	3 (1.7)	0.0005
Treatment able to induce K variations, n (%)*
Potassium-sparing diuretics	31 (26)	12 (7)	0.0001
IV Mg supplement	22 (18.4)	4 (2.3)	0.0001
Furosemide	45 (37.8)	46 (26.3)	0.054
Tiazide	2 (1.6)	2 (1.1)	0.713
Corticosteroid	46 (38.6)	53 (30.9)	0.219
Insulin	19 (16.9)	19 (11.1)	0.288
β2-agonists	6 (5.04)	7 (4.09)	0.776
Penicillin	17 (14.2)	15 (8.7)	0.181
NSAID	5 (4.2)	8 (4.6)	1
Digoxin	0	2 (1.1)	0.514
Insulin	19 (16.9)	19 (11.1)	0.288
RAS-blocker	17 (14.2)	20 (11.6)	0.592
Status at the end of F-U
Follow-up, days (± SD)	14.1 (7.5)	11.4 (7.1)	0.002
Rhabdomyolysis, n (%)	2 (1.7)	4 (2.4)	1
Arrhytmia, n (%)	1 (0.8)	1 (5.8)	1
Acute kidney disease, n (%)	22 (18.4)	35 (20.4)	0.764
ICU transfer, n (%)	11 (9.2)	29 (16.9)	0.083
Death of, n (%)	17 (14.2)	28(16.3)	0.742

ICU denotes intensive care unit, n number of patients, SD standard deviation, SOFA sequential organ failure assessment

*T-test or Mann Whitney test as appropriate; χ2 test for categorical variable

Results are reported as mean ± SD unless otherwise stated

Half of the hypokalemic patients had hypocalcemia compared to 33.6% of normokalemic patients (P = 0.13). Serum calcium and magnesium concentration were significantly lower in hypokalemic than normokalemic patients (Table 2). Patients with hypokalemia had a longer follow-up (P = 0.002) compared to normokalemic patients likely for a severe course of COVID-19, as showed by a statistically significant higher SOFA score (P = 0.014) at the admission. Mean serum creatinine of hypokalemic patients was 0.9 ± 0.9 mg/dl (Table 2); the rate of acute kidney injury was similar in the two groups (P = 0.764).

Table 2

Main lab tests of hypokalemic and normokaliemic patients at admission

Lab test, Mean (± SD)	Hypokalemic	Normokalemic	P value*
Hemoglobin, g/L	12.1 (1.6)	12.8 (1.793)	0.001
White cells, mm3	7393 (5044)	8156.6 (8228.1)	0.750
Platelets, 109/L	252.3 (119.3)	243.2 (116.1)	0.482
Glycemia, mg/dL	105.2 (35.9)	110.6 (54.4)	0.656
Potassium, mmoL/L	3.1 (0.1)	4.0 (0.3)	< 0.0001
Sodium, mmoL/L	137.4 (3.9)	137.2 (3.6)	0.818
Calcium, mg/L	8.3 (0.5)	8.7 (0.6)	0.001
Magnesium, mmoL/L	2.1 (0.3)	2.6 (0.3)	0.028
Chloride, mmoL/L	99.6 (4.5)	100.2 (4.4)	0.509
Creatinine, mg/ dl	0.9 (0.9)	1.1 (1.3)	< 0.0001
Urea, mg/dl	55.31 (47.8)	52 (30.3)	0.564
Albumin, gr/dl	3.2 (0.5)	3.1 (05)	0.519
Urine K+ (spot)	30.1 (16.7)	36.5 (21.8)	0.229
Urine Creatinine (spot, mg/dL)	66.5 (79.1)	84 (62.7)	0.477
Urine protein-to-creatinine, mg/mg	0.5 (0.5)	0.4 (0.31)	0.300
D-dimer, mg/L	2478 (4070.8)	3045.7 (5718.3)	0.826
Alanine amino-transferase, U/L	45.9(37.2)	109.65 (761.7)	0.371
Lactate dehydrogenase, U/L	687.2 (310)	812.2 (1914.1)	0.348
CPK, U/L	556.5 (1556.2)	495.6 (1462,1)	0.739
Ferritin, mg/dl	867 (416.7)	856.4 (824.1)	0.373
Bilirubin, mg/dl	0.7 (0.5)	0.7 (0.7)	0.301
C-reactive protein, mg/dl	10.2 (9.9)	9.8 (7.6)	0.524

Results are reported as mean ± SD unless otherwise stated

*T-test or Mann Whitney test as appropriate. In hypokaliemic patients lab tests were obtained at diagnosis of hypokalemia

Therapeutic agents are known to induce hypokalemia (diuretics, corticosteroids, β2-agonists, NSAID, insulin and penicillin) were investigated in both groups (Table 1). There were no significant differences between groups in terms of prevalence.

Potassium excretion

Urine potassium-to-creatinine ratio was available only in a minority of hypokalemic patients (n = 45; 36.1%). A high urinary excretion of potassium (urine potassium-to-creatinine ratio > 1.5 mEq/mmol) was documented in 43 (95.5%) patients. Twenty-three patients (53.4%) with high urinary potassium excretion were on diuretic therapy (furosemide) and 10 (23.3%) were on corticosteroids at the time of serum K measurement. The remaining 10 patients (23.3%) with augmented kaliuresis had normal serum magnesium levels and 90% had low sodium excretion (FENa < 1%) (Fig. 1). Acid–base status of these ten patients was consistent with metabolic alkalosis (70%), respiratory alkalosis (10%), respiratory acidosis(10%) and normal acid–base status (10%).

Therapy in hypokalemic patients

Potassium supplements were prescribed to correct hypokalemia (Table 2). Salts of potassium (potassium chloride) were administered via the oral route in 28 (23.5%) patients and IV in 14 (11.7%) patients, both oral route and IV were used in one (0.8%) patient.

Intravenous magnesium sulfate (83 gr of magnesium sulfate or 673.9 mEq/l of magnesium) was administered in 22 (18.4%) patients for hypomagnesemia.

Regarding the total amount of K supplements, 3600 mq (47.6 g) of potassium chloride were administered intravenously and 1536 mEq/L (20.3 gr) were administered orally. During the whole hospital stay, each potassium chloride-treated patient received a mean of 128.5 and 109.7 mEq of potassium chloride intravenously and orally, respectively.

Potassium-sparing diuretics were largely administered among hypokalemic patients (26%) compared to normokalemia (7%) likely for its pharmacological action targeted to maintain a normal kalemia and prevent hypokalemia (Table 2). Forty-five (37.5%) patients were on diuretic therapy with furosemide and two (1.6%) with thiazide at the time of diagnosis with hypokalemia. Hypertension (57.4%), cardiovascular disease (38.2%) and renal impairment (31.9%) were the potential causes of diuretic use in these patients.

Risk factors and outcome

A chi-square test did not reveal significant differences between hypokalemic and normokaliemic patients with CPK > 1000 UI/L (P = 0.396), CKP > 5000UI/L (P = 0.69) and arrhythmia (P = 0.79). Univariate analysis showed that female sex, corticosteroids and diuretics were significantly associated with hypokalemia in our cohort of patients (Table 3). Multivariate regression model analysis showed that female sex (P = 0.003; OR 2.44; 95% CI 1.36–4.37) and diuretic therapy (P = 0.027; OR 1.94; 95% CI 1.08–3.48) were significant risk factors for hypokalemia (Table 4). Survival regression analysis showed that hypokalemia adjusted for sex, age and SOFA score was not associated with transition to ICU (OR 0.52; 95% CI 0.228–1.212, P = 0.131), in-hospital mortality (OR 0.47; 95% CI 0.170–1.324, P = 0.154) and composite outcome of ICU transfer or in-hospital mortality (OR 0.48; 95% CI 0.222–1.047; P = 0,065).

Table 3

Predictive factors of hypokalemia revealed by univariate logistic regression analysis

	HR	CI (95%)		p value
Age	1.01	0.99	1.03	0.31
PO2/FiO2	1.00	0.97	1.00	0.30
Sex
Female	2.64	1.55	4.48	< 0.001
SOFA	1.00	1.00	1.00	0.23
Serum magnesium	0.31	0.09	1.01	0.05
Alkalosis	1.55	0.94	2.57	0.09
Corticosteroid
Yes/No	1.66	1.01	2.74	0.05
Diuretic Therapy
Yes/No	2.00	1.22	3.27	0.01

Table 4

Multivariate regression model of predictive factors of hypokalemia

	HR	CI (95%)		p value
Alkalosis	1.50	0.89	2.53	0.128
Diuretic Therapy	1.94	1.08	3.48	0.027
Sex
Female	2.44	1.36	4.37	0.003
Corticosteroid	1.25	0.69	2.27	0.467

Discussion

Hypokalemia has been mentioned as a potential manifestation of COVID-19 [7] due to the interaction of SARS-CoV-2 with the renin–angiotensin–aldosterone system [17]. Prevalence and underlying etiologic mechanisms of hypokalemia in COVID-19 have been poorly documented. The results of our study showed that hypokalemia was a common electrolytic abnormality among COVID-19 patients. Hypokalemia was found in 41% of non-ICU admitted patients during hospitalization for severe symptoms of SARS-CoV-2 infection. It occurred in about half of the patients within the first 24 from admission and was principal of mild severity and rapid resolution. Nevertheless, administration of large amounts of potassium and magnesium supplements as well as potassium-sparing diuretics were utilized to correct low serum potassium concentrations.

We noticed that patients who experienced hypokalemia had significantly longer hospitalization than controls. Likely the significantly higher rate of respiratory symptoms (dyspnea and cough) and the worse SOFA score (2.7 vs 2.2) at admission reflected a more severe systemic inflammatory response leading to a prolonged hospital stay than normokalemic patients. Multivariate analysis of risk factors for hypokalemia showed that diuretic therapy and female sex were significantly associated with a serum potassium level < 3.5 mEq/L.

Diuretics are pharmacological agents largely used to treat hypertension and prevent fluid overload. Long-term administration of this class of drugs is widely known to cause hypokalemia and other electrolyte imbalances [18], as they act by inhibiting reabsorption of electrolytes in the renal tubules. A slightly higher prevalence of hypertension, cardiovascular disease and renal impairment in hypokalemic than normokalemic patients may be a plausible explanation of the higher use of diuretics in this group of patients. In addition, diuretics together with alkalosis and hypoalbuminemia might also be involved in causing hypocalcemia in patients with hypokalemia.

The risk of hypokalemia was up to 2.44-fold higher in women than men. Although there are no apparent causes that interlink female sex with hypokalemia, experimental studies conducted in the 50s [19] and then confirmed in the 90s, [11] showed that women, especially aged ones, have less exchangeable body potassium than other subsets of the population. The women are, therefore, at high risk to develop hypokalemia because they have depleted deposits of potassium due to their different body composition, characterized by less amount of extracellular water compared to men.

Hypokalemia is one of the most frequent electrolyte disorders in hospitalized patients. Severe hypokalemia is associated with potentially life-threatening complications such as cardiac dysrhythmias, paralysis and rhabdomyolysis especially in subjects with underlying cardiovascular disease [20, 21].

We noticed a similar rate of CKP elevation (> 1000 UI/L), rhabdomyolysis (CPK > 5000 UI/L) or arrhythmia between hypokalemic and normokalemic patients. Hypokalemia per se was not associated with poor outcome in term of ICU transfer (OR 0.525; 95% CI 0.228–1.212; P = 0.131), in-hospital mortality (OR 0.47; 95% CI 0.170–1.324; P = 0.154) and composite outcome ICU transfer/in-hospital mortality (OR 0.48; 95% CI 0.222–1.047; P = 0.065). Likely, the mild severity of the disorder (90.7% had serum levels of potassium between 3 and 3.4 mEq/L) and the rapid recovery of normal serum potassium levels may explain the null effect of hypokalemia on major outcomes in our cohort of patients. Despite these reassuring data, serum potassium should be carefully monitored in this vulnerable subset of the population for the risk of potentially lethal arrhythmia. Hypokalemia may act by prolonging QT interval in COVID-19 patients with abnormal QT interval due to the large use of off-label agents for SARS-CoV-2 infection such as azithromycin and hydroxychloroquine. [22].

Multiple mechanisms underlying hypokalemia include diuretic therapy, gastrointestinal loss, anorexia or alkalosis [23]. More rarely, congenital or acquired tubular defect, side effects of drugs or transient tubular ischemia induce tubular potassium losses due to the disruption of renal electrolytes handling [24, 25]. Hyperaldosteronism, primitive or as a consequence of activation of the renin-angiotensin system, is also known to stimulate urinary potassium excretion. Compared to the general population, COVID-19 patients experienced at least three predisposing risk factors for hypokalemia. First, respiratory alkalosis due to hypoxia-driven hyperventilation may provoke transcellular shifts with increased intracellular uptake. Second, anorexia, as a consequence of continuative use of face mask or ventilation helmet or status of severe illness, may lead to a decrease in potassium intake. Third, diarrhea due to medication (e.g., lopinavir/ritonavir) or the cytopathic effect of the virus on the gastrointestinal cells may be a frequent cause of potassium losses from the digestive tract.

Few reports have documented an interplay between hypokalemia and coronavirus infection so far. Hypokalemia has been reported during the SARS-CoV-1 outbreak in Canada. Here, Booth et al. [9] reported a low potassium level in 62 out of 144 (43%) patients (mean serum potassium, 3.2 mEq/l) during hospitalization. Hypokalemia was not isolated and occurred with other electrolyte abnormalities such as hypomagnesemia and hypophosphatemia. The authors were unable to establish clear evidence for electrolyte imbalance and suggested that it may be a clinical manifestation of the infection or a nephrotoxic effect of ribavirin or other medicaments on renal electrolytes handling. The abstract of a Chinese article, reported hypokalemia as a side effect of glucocorticoids in SARS-CoV-1 infected patients [10]. These agents increase urinary potassium excretion through activation of the mineralocorticoid receptor on the renal tubular cells [26]. A recent study conducted on 179 COVID-19 patients admitted to the hospital in Wenzhou, China, reported that hypokalemia was a common electrolytic disorder and affected 55% of patients. Hypokalemic patients had an increased urinary K output compared with the normal group with normokalemia. Based on these results, the authors suggested that the primary cause of hypokalemia was consistent with the disruption of ACE2 by the binding of SARS-CoV-2. [27]

To evaluate tubular potassium handling in our cohort of COVID-19 patients, we investigated the magnitude of potassium secretion in a group of hypokalemic patients with available urine electrolytes. In line with the findings of the above-mentioned study [27], urine potassium-to-creatinine ratio was increased in 95.5% of patients who underwent urinary examination (n = 45). In about three-fourths of the urinary sample, the high urinary K excretion was associated with diuretic and corticosteroid therapy (kaliuretic agents), whereas causes were unclear in the remaining patients (n = 10, 23.3%).

Bringing it all together, etiology of hypokalemia in our COVID-19 patients seems multifactorial and is likely associated with augmented urinary loss. Cytopathic effect of SARS-CoV-2 infection [11] and the indirect effect of cytokines triggered by viral infection [28] on renal tubules may induce a COVID-19-related potassium-losing tubulopathy. However, determining the exact etiology of hypokalemia is challenging in the presence of multiple interfering effects from therapeutic agents. Selection bias arising from the retrospective nature of our study, absence of a control group in the evaluation of urinary potassium excretion and lack of plasma renin and aldosterone measurements evaluating the activity of the RASS further limited risk assessment for hypokalemia in our study. Despite these limitations, we collected comprehensive data on all prescribed medications and accompanying acid–base disorders that provided relevant information on key determinants of hypokalemia in COVID-19.

Conclusions

Hypokalemia was a frequent electrolyte disorder in hospitalized patients with COVID-19. It was principally of mild severity and of rapid solution. Our findings support the need to frequently measure the level of serum potassium along with urine potassium-to-creatinine ratio or 24 h potassium excretion in COVID-19 patients to improve the complex management of these subjects. Low potassium level should be supplemented per os or IV, and a careful assessment of the ECG should be performed, especially in concomitance of potentially arrhythmogenic drugs.

Although hypokalemia was not associated with mortality in our cohort of patients, it may be a life-threatening condition (e.g., in long QT patients) if it remains untreated.

Below is the link to the electronic supplementary material.

Supplementary file1 (Docx 82 kb)